Ovid Therapeutics Inc. (OVID): Price and Financial Metrics


Ovid Therapeutics Inc. (OVID): $2.39

-0.04 (-1.65%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add OVID to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

OVID POWR Grades

  • Sentiment is the dimension where OVID ranks best; there it ranks ahead of 98.07% of US stocks.
  • The strongest trend for OVID is in Growth, which has been heading up over the past 177 days.
  • OVID's current lowest rank is in the Quality metric (where it is better than 33.74% of US stocks).

OVID Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for OVID is 0.01 -- better than merely 8.68% of US stocks.
  • With a price/sales ratio of 115.63, OVID THERAPEUTICS INC has a higher such ratio than 97.72% of stocks in our set.
  • As for revenue growth, note that OVID's revenue has grown -99.32% over the past 12 months; that beats the revenue growth of merely 0.71% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to OVID THERAPEUTICS INC, a group of peers worth examining would be HCWB, APM, TDUP, TVTX, and ACAD.
  • OVID's SEC filings can be seen here. And to visit OVID THERAPEUTICS INC's official web site, go to www.ovidrx.com.

OVID Valuation Summary

  • OVID's price/sales ratio is 121; this is 5661.9% higher than that of the median Healthcare stock.
  • Over the past 70 months, OVID's EV/EBIT ratio has gone up 9.2.

Below are key valuation metrics over time for OVID.

Stock Date P/S P/B P/E EV/EBIT
OVID 2023-01-30 121.0 1.2 -2.6 -1.9
OVID 2023-01-27 122.5 1.3 -2.6 -1.9
OVID 2023-01-26 120.1 1.2 -2.5 -1.9
OVID 2023-01-25 116.1 1.2 -2.5 -1.8
OVID 2023-01-24 116.1 1.2 -2.5 -1.8
OVID 2023-01-23 116.6 1.2 -2.5 -1.8

OVID's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • OVID has a Quality Grade of C, ranking ahead of 59.21% of graded US stocks.
  • OVID's asset turnover comes in at 1.419 -- ranking 13th of 682 Pharmaceutical Products stocks.
  • QURE, ACER, and SCYX are the stocks whose asset turnover ratios are most correlated with OVID.

The table below shows OVID's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 1.419 1 -10.143
2021-03-31 1.963 1 -8.584
2020-12-31 0.184 1 18.535
2020-09-30 0.099 1 -10.445
2020-06-30 0.000 NA -8.770
2020-03-31 0.000 NA -6.119

OVID Price Target

For more insight on analysts targets of OVID, see our OVID price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $4.75 Average Broker Recommendation 1.5 (Moderate Buy)

OVID Stock Price Chart Interactive Chart >

Price chart for OVID

OVID Price/Volume Stats

Current price $2.39 52-week high $3.55
Prev. close $2.43 52-week low $1.40
Day low $2.36 Volume 118,400
Day high $2.46 Avg. volume 64,367
50-day MA $2.02 Dividend yield N/A
200-day MA $2.02 Market Cap 168.42M

Ovid Therapeutics Inc. (OVID) Company Bio


Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company was founded in 2014 and is based in New York City, New York.


OVID Latest News Stream


Event/Time News Detail
Loading, please wait...

OVID Latest Social Stream


Loading social stream, please wait...

View Full OVID Social Stream

Latest OVID News From Around the Web

Below are the latest news stories about OVID THERAPEUTICS INC that investors may wish to consider to help them evaluate OVID as an investment opportunity.

Ovid Therapeutics Inc. (NASDAQ:OVID) has caught the attention of institutional investors who hold a sizeable 29% stake

If you want to know who really controls Ovid Therapeutics Inc. ( NASDAQ:OVID ), then you'll have to look at the makeup...

Yahoo | January 22, 2023

Ovid Therapeutics Dosed Healthy Volunteers with OV329 in Phase 1 Trial

A Potential, Next-Generation GABA-Aminotransferase Inhibitor for Rare Epilepsies with Limited Treatment OptionsNEW YORK, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company developing medicines designed to conquer epilepsies and meaningfully improve the lives of people affected by brain disorders, dosed healthy volunteers with OV329 in late December 2022, as part of a Phase 1 study. The Company is conducting the study to evaluate the safety and ta

Yahoo | January 5, 2023

Ovid Therapeutics to Present Data on Its Epilepsy Programs at American Epilepsy Society Annual Meeting (2022)

Preclinical data demonstrate potential efficacy and safety of OV329 at low, chronic dosing, suggesting an improved profile compared to other GABA-aminotransferase inhibitors Data from the NIH/NINDs Epilepsy Therapy Screening Program demonstrate that OV329 confers protection from seizure activity in several treatment-resistant animal models New preclinical data on OV350 underscore the potential of activating the KCC2 to alleviate refractory status epilepticus and limit neuronal damage NEW YORK, D

Yahoo | December 2, 2022

Is Ovid Therapeutics (NASDAQ:OVID) In A Good Position To Deliver On Growth Plans?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Yahoo | November 17, 2022

Ladenburg Thalmann & Co. Keeps Their Buy Rating on Ovid Therapeutics (OVID)

In a report released today, Michael Higgins from Ladenburg Thalmann & Co. maintained a Buy rating on Ovid Therapeutics (OVID - Research Report), with a price target of $7.00. The company's shares closed yesterday at $1.49.Higgins covers the Healthcare sector, focusing on stocks such as Palatin Technologies, Eiger Biopharmaceuticals, and Marinus. According to TipRanks, Higgins has an average return of 2.9% and a 28.57% success rate on recommended stocks. Ovid Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $4.75.See the top stocks recommended by analysts >>The company has a one-year high of $3.70 and a one-year low of $1.41.

Austin Angelo on TipRanks | November 9, 2022

Read More 'OVID' Stories Here

OVID Price Returns

1-mo 27.13%
3-mo 62.59%
6-mo 7.66%
1-year -17.87%
3-year 24.80%
5-year -28.97%
YTD 28.49%
2022 -42.06%
2021 38.96%
2020 11.33%
2019 71.49%
2018 -75.48%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8225 seconds.